Postoperative adjuvant external-beam radiation therapy for cancers of the eyelid and conjunctiva

Adam Hsu, Steven J. Frank, Matthew Ballo, Adam S. Garden, William H. Morrison, David I. Rosenthal, Elham Hatef, Bita Esmaeli

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

PURPOSE: To outline the indications for and our experience with postoperative adjuvant external-beam radiotherapy (EBRT) in patients with eyelid or conjunctival cancers. METHODS: Twenty consecutive patients with primary eyelid or conjunctival cancer treated with surgical resection followed by postoperative EBRT between January 2000 and September 2006 were included. The indications for postoperative EBRT, type and dose of EBRT, oculoplastic reconstructive procedures, timing of EBRT in relation to reconstructive procedures, and the ocular side effects of EBRT were recorded. RESULTS: Sixteen women and 4 men ranged in age from 44 to 86 years (median, 64 years). The oculoplastic procedures included local flaps or direct closure of eyelid defect (12), tarsoconjunctival flap (6), full-thickness skin grafts (6), amniotic membrane grafts (2), other conjunctival reconstruction (2), tarsoconjunctival graft (1), and lacrimal stenting (1). The total radiation dose ranged from 26 to 63 Gy (median, 60 Gy). The indications for postoperative EBRT included aggressive histology, recurrent tumor, microscopic perineural invasion, advanced-stage disease, and microscopically positive or "close" margins. EBRT started 5 to 12 weeks (median, 7 weeks) after reconstructive procedures. The follow-up time ranged from 7 to 50 months (mean, 24 months). Thirteen patients experienced dry eye syndrome; 3 keratinization of conjunctiva; and 1 each blepharitis, trichiasis, radiation retinopathy/optic neuropathy, and exposure keratopathy. CONCLUSIONS: Postoperative EBRT can be used as adjuvant therapy after surgical resection of eyelid or conjunctival cancers and may obviate more radical surgery such as orbital exenteration in some patients. The ocular side effects from EBRT were relatively minor in most patients.

Original languageEnglish (US)
Pages (from-to)444-449
Number of pages6
JournalOphthalmic Plastic and Reconstructive Surgery
Volume24
Issue number6
DOIs
StatePublished - Nov 1 2008
Externally publishedYes

Fingerprint

Conjunctiva
Eyelids
Radiotherapy
Neoplasms
Transplants
Trichiasis
Dry Eye Syndromes
Blepharitis
Radiation
Optic Nerve Diseases
Amnion
Tears
Histology
Skin

All Science Journal Classification (ASJC) codes

  • Surgery
  • Ophthalmology

Cite this

Postoperative adjuvant external-beam radiation therapy for cancers of the eyelid and conjunctiva. / Hsu, Adam; Frank, Steven J.; Ballo, Matthew; Garden, Adam S.; Morrison, William H.; Rosenthal, David I.; Hatef, Elham; Esmaeli, Bita.

In: Ophthalmic Plastic and Reconstructive Surgery, Vol. 24, No. 6, 01.11.2008, p. 444-449.

Research output: Contribution to journalArticle

Hsu, Adam ; Frank, Steven J. ; Ballo, Matthew ; Garden, Adam S. ; Morrison, William H. ; Rosenthal, David I. ; Hatef, Elham ; Esmaeli, Bita. / Postoperative adjuvant external-beam radiation therapy for cancers of the eyelid and conjunctiva. In: Ophthalmic Plastic and Reconstructive Surgery. 2008 ; Vol. 24, No. 6. pp. 444-449.
@article{b4634796a64541dea4d8b266b12dbd0c,
title = "Postoperative adjuvant external-beam radiation therapy for cancers of the eyelid and conjunctiva",
abstract = "PURPOSE: To outline the indications for and our experience with postoperative adjuvant external-beam radiotherapy (EBRT) in patients with eyelid or conjunctival cancers. METHODS: Twenty consecutive patients with primary eyelid or conjunctival cancer treated with surgical resection followed by postoperative EBRT between January 2000 and September 2006 were included. The indications for postoperative EBRT, type and dose of EBRT, oculoplastic reconstructive procedures, timing of EBRT in relation to reconstructive procedures, and the ocular side effects of EBRT were recorded. RESULTS: Sixteen women and 4 men ranged in age from 44 to 86 years (median, 64 years). The oculoplastic procedures included local flaps or direct closure of eyelid defect (12), tarsoconjunctival flap (6), full-thickness skin grafts (6), amniotic membrane grafts (2), other conjunctival reconstruction (2), tarsoconjunctival graft (1), and lacrimal stenting (1). The total radiation dose ranged from 26 to 63 Gy (median, 60 Gy). The indications for postoperative EBRT included aggressive histology, recurrent tumor, microscopic perineural invasion, advanced-stage disease, and microscopically positive or {"}close{"} margins. EBRT started 5 to 12 weeks (median, 7 weeks) after reconstructive procedures. The follow-up time ranged from 7 to 50 months (mean, 24 months). Thirteen patients experienced dry eye syndrome; 3 keratinization of conjunctiva; and 1 each blepharitis, trichiasis, radiation retinopathy/optic neuropathy, and exposure keratopathy. CONCLUSIONS: Postoperative EBRT can be used as adjuvant therapy after surgical resection of eyelid or conjunctival cancers and may obviate more radical surgery such as orbital exenteration in some patients. The ocular side effects from EBRT were relatively minor in most patients.",
author = "Adam Hsu and Frank, {Steven J.} and Matthew Ballo and Garden, {Adam S.} and Morrison, {William H.} and Rosenthal, {David I.} and Elham Hatef and Bita Esmaeli",
year = "2008",
month = "11",
day = "1",
doi = "10.1097/IOP.0b013e31818be098",
language = "English (US)",
volume = "24",
pages = "444--449",
journal = "Ophthalmic Plastic and Reconstructive Surgery",
issn = "0740-9303",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Postoperative adjuvant external-beam radiation therapy for cancers of the eyelid and conjunctiva

AU - Hsu, Adam

AU - Frank, Steven J.

AU - Ballo, Matthew

AU - Garden, Adam S.

AU - Morrison, William H.

AU - Rosenthal, David I.

AU - Hatef, Elham

AU - Esmaeli, Bita

PY - 2008/11/1

Y1 - 2008/11/1

N2 - PURPOSE: To outline the indications for and our experience with postoperative adjuvant external-beam radiotherapy (EBRT) in patients with eyelid or conjunctival cancers. METHODS: Twenty consecutive patients with primary eyelid or conjunctival cancer treated with surgical resection followed by postoperative EBRT between January 2000 and September 2006 were included. The indications for postoperative EBRT, type and dose of EBRT, oculoplastic reconstructive procedures, timing of EBRT in relation to reconstructive procedures, and the ocular side effects of EBRT were recorded. RESULTS: Sixteen women and 4 men ranged in age from 44 to 86 years (median, 64 years). The oculoplastic procedures included local flaps or direct closure of eyelid defect (12), tarsoconjunctival flap (6), full-thickness skin grafts (6), amniotic membrane grafts (2), other conjunctival reconstruction (2), tarsoconjunctival graft (1), and lacrimal stenting (1). The total radiation dose ranged from 26 to 63 Gy (median, 60 Gy). The indications for postoperative EBRT included aggressive histology, recurrent tumor, microscopic perineural invasion, advanced-stage disease, and microscopically positive or "close" margins. EBRT started 5 to 12 weeks (median, 7 weeks) after reconstructive procedures. The follow-up time ranged from 7 to 50 months (mean, 24 months). Thirteen patients experienced dry eye syndrome; 3 keratinization of conjunctiva; and 1 each blepharitis, trichiasis, radiation retinopathy/optic neuropathy, and exposure keratopathy. CONCLUSIONS: Postoperative EBRT can be used as adjuvant therapy after surgical resection of eyelid or conjunctival cancers and may obviate more radical surgery such as orbital exenteration in some patients. The ocular side effects from EBRT were relatively minor in most patients.

AB - PURPOSE: To outline the indications for and our experience with postoperative adjuvant external-beam radiotherapy (EBRT) in patients with eyelid or conjunctival cancers. METHODS: Twenty consecutive patients with primary eyelid or conjunctival cancer treated with surgical resection followed by postoperative EBRT between January 2000 and September 2006 were included. The indications for postoperative EBRT, type and dose of EBRT, oculoplastic reconstructive procedures, timing of EBRT in relation to reconstructive procedures, and the ocular side effects of EBRT were recorded. RESULTS: Sixteen women and 4 men ranged in age from 44 to 86 years (median, 64 years). The oculoplastic procedures included local flaps or direct closure of eyelid defect (12), tarsoconjunctival flap (6), full-thickness skin grafts (6), amniotic membrane grafts (2), other conjunctival reconstruction (2), tarsoconjunctival graft (1), and lacrimal stenting (1). The total radiation dose ranged from 26 to 63 Gy (median, 60 Gy). The indications for postoperative EBRT included aggressive histology, recurrent tumor, microscopic perineural invasion, advanced-stage disease, and microscopically positive or "close" margins. EBRT started 5 to 12 weeks (median, 7 weeks) after reconstructive procedures. The follow-up time ranged from 7 to 50 months (mean, 24 months). Thirteen patients experienced dry eye syndrome; 3 keratinization of conjunctiva; and 1 each blepharitis, trichiasis, radiation retinopathy/optic neuropathy, and exposure keratopathy. CONCLUSIONS: Postoperative EBRT can be used as adjuvant therapy after surgical resection of eyelid or conjunctival cancers and may obviate more radical surgery such as orbital exenteration in some patients. The ocular side effects from EBRT were relatively minor in most patients.

UR - http://www.scopus.com/inward/record.url?scp=61449393577&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=61449393577&partnerID=8YFLogxK

U2 - 10.1097/IOP.0b013e31818be098

DO - 10.1097/IOP.0b013e31818be098

M3 - Article

VL - 24

SP - 444

EP - 449

JO - Ophthalmic Plastic and Reconstructive Surgery

JF - Ophthalmic Plastic and Reconstructive Surgery

SN - 0740-9303

IS - 6

ER -